Session 1:
Drug Discovery: An Overview of a Continuously
Changing Process
An Overview Of Modern Drug Discovery: How HTS Will Improve the Productivity
of the Pharmaceutical Industry
Bob Hertzberg - GlaxoSmithKline, USA
Drugs From the Sea: A Case Study
- PharmaMar, Spain
High-Throughput Screening and Cellular Biology at Serono
Karen Yeow - Serono Pharmaceutical Research Institute,
Switzerland
Session 2:
Application of High Throughput Technologies in Drug Discovery
Current HTS Approaches to Drug Discovery
Robert Campbell - Eli Lilly & Co, USA
Asset: Industrial Automation for uHTS
Juan Antonio Mostacero - GlaxoSmithKline, Spain
Innovative HTS Technologies: Nano-Screening and Affinity-Selection
Lorenz Mayr - Novartis Pharmaceuticals, Switzerland
Kinase Inhibitors: Comparison of a Bioluminescent and a Microfluidic
Assay Format
Aimo Kannt - Aventis, Germany
High Throughput Techniques for Measurement of Physiochemical Properties
of Drugs to Aid the Prediction of their ADME Characteristics
John Comer - Sirius Analytical Instruments Ltd., UK
Session 3:
Computational Tools to Drive Drug Discovery
Problems, Prospects and Solutions for Global Informatics in the
Drug Discovery Business
Bryn Roberts - AstraZeneca, UK
Challenges in Drug Design
Modesto Orozco - Institut de Recerca Biomèdica, University
of Barcelona, Spain
Automated Routine Quality Control in High-Throughput Screening
Drives Improvements in Design Of Screening Experiments To Provide
a Basis For Biological and Chemical Compound Profiling
Stephan Heyse - GeneData AG, Switzerland
Session 4:
The Role of Academia in Target Selection and Validation
Manipulating the Mouse Genome: A New Generation of Animal Models
for Oncology Drug Discovery
Mariano Barbacid - Centro Nacional de Investigaciones Oncológicas
(CNIO) Spain
Study Of Cellular Protein: Targets For Modification By Cyclopentenone
Prostaglandins
Dolores Pérez-Sala - Centro de Investigaciones Biológicas,
Consejo Superior de Investigaciones Científicas.,
Spain
Metabolic Footprinting and Genetic Programming: A High Throughput,
High Information Approach to Mutant Characterization, Mode of Action
and Functional Genomics
Douglas B. Kell - UMIST, UK
MRC Technology's Assay Development Group: Converting Basic Science
into New Targets for HTS
Catherine A. Kettleborough - MRC Technology, UK
High Throughput Proteomics in the Validation of Therapeutic Targets
José María Mato - University of Navarra, Spain
Session 5:
From Proteins to Cells: Accelerating Cell Biology
Development and Utilization
of the acCellerator™ Cell
Culturing System Within the Drug Discovery Pipeline
Gary Allenby - AstraZeneca, UK
Accelerating Endosomes: High Content Screening Assays of Endocytosis
Neil Emans - Institute for Molecular Biotechnology, Aachen University,
Germany
Solutions for the Challenges in High-throughput Cell Based Screening
Johan Geysen - Union Biometrica N.V., Belgium
Modulation of Protein Translocation as an Alternative to Inhibition
of Catalytic Activity: Selective Hits from Redistribution™-Based
High
Throughput Screening
Steven Butcher - BioImage CSO, Denmark
New Cellular Assay Formats For Miniaturized HTS
Julianwölcke - Evotec Oai, Germany
Session 6:
Sources of Chemical Diversity: What Goes Through the Screen?
Compound Management: Optimizing quality and Accessibility of the
Screening Library
Pierre Acklin - Novartis Pharma AG, Switzerland
The "Latent Hit" Concept: A Medicinal Chemistry Approach
to Hit Generation
Jordi Mestres - Municipal Institute of Medical Research and
University Pompeu Fabra, Spain
Marrying Targets and Compounds
Ricardo Macarron - GlaxoSmithKline, USA
A New Model for Utilizing Chemical Diversity from Natural Products
Anthony Buss - Merlion, Singapore
|
